Skip to main content

Table 1 Population characteristics according to arm of treatment

From: Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial

Characteristics

Clarithromycin-based regimen (n = 116)

Levofloxacin-based regimen (n = 117)

Test statistics

P

Sex

 Male (%)

74 (63.8)

64 (54.7)

2.00

0.350

 Female

42 (36.2)

53 (45.3)

Age, years mean ± SD

41.31 ± 13.2

42.92 ± 12.77

0.95

0.290

 Marital status

    

 Married

71 (61.2)

78 (66.7)

1.59

0.663

 Single

45 (38.8)

39 (33.3)

Residence

    

 Urban

103 (88.8)

99 (84.6)

0.88

0.350

 Rural

13 (11.2)

18 (15.4)

 Smoking

    

 Smokers

33 (28.4)

27 (23.1)

0.37

0.560

Nonsmoker

83 (71.6)

90 (76.9)

Medical history

    

 No chronic disease

70 (60.3)

68 (58.1)

3.70

0.590

 Chronic disease

46 (39.7)

49 (41.9)

The most annoying C/O

    

 Heart burn

9 (7.8)

11 (9.4)

0.82

0.850

 Epigastric pain

83 (71.6)

86 (73.5)

 Vomiting

16 (13.8)

12 (10.3)

 Reflux laryngitis

8 (6.9)

8 (6.8)

Detection method

    

Urea breath test

72 (62.1)

45 (38.5)

0.15

0.479

Stool antigen

43 (37.1)

29 (24.8)

Endoscopy

31 (26.7)

13 (11.1)

Treatment

    

 Treatment duration

13.94 ± 0.03

13.93 ± 0.03

0.10

0.920